{{medical}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 454958164
| IUPAC_name = 1-[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]piperazine
| image = Vortioxetine.svg
| width = 150
| image2 = Vortioxetine ball-and-stick model.png
| width2 = 175

<!--Clinical data-->
| pronounce = {{IPAc-en|v|ɔːr|t|i|ˈ|ɒ|k|s|ə|t|iː|n}} {{respell|vor|tee|OK|sə|teen}}
| tradename =  心达悦、Trintellix、Brintellix等
| licence_EU = yes
| licence_US = Vortioxetine
| pregnancy_US = C
| pregnancy_AU = B3
| pregnancy_AU_comment = 
<ref>{{cite web|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2014-PI-01635-1&d=2017071216114622483|title=TGA eBS - Product and Consumer Medicine Information Licence|author=|date=|website=www.ebs.tga.gov.au|accessdate=29 April 2018|deadurl=no|archiveurl=https://web.archive.org/web/20180429013449/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2014-PI-01635-1&d=2017071216114622483|archivedate=29 April 2018|df=}}</ref>
| legal_status = Rx-only
| routes_of_administration = [[Oral_administration|By mouth]] (film-coated [[Tablet_(pharmacy)|tablets)]]

<!--Pharmacokinetic data-->
| bioavailability = 75% (peak at 7–11 hours)
| protein_bound = 98%
| metabolism = Extensive [[Liver|hepatic]], primarily [[CYP2D6|CYP2D6]]-mediated oxidation
| elimination_half-life = 66 hours
| excretion = 59% in urine, 26% in feces

<!--Identifiers-->
| IUPHAR_ligand = 7351
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 508233-74-7
| ATC_prefix = N06
| ATC_suffix = AX26
| ATC_supplemental = 
| PubChem = 9966051
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 8141643
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB09068
| synonyms = Lu AA21004
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 76016
| KEGG = D10184
| KEGG_Ref = {{keggcite|changed|kegg}}
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 3O2K1S3WQV

<!--Chemical data-->
| C = 18 | H = 22 | N = 2 | S = 1
| molecular_weight = 298.45 g/mol (379.36 as hydrobromide)
| smiles = CC(C=C(C)C=C1)=C1SC2=C(N3CCNCC3)C=CC=C2
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = YQNWZWMKLDQSAC-UHFFFAOYSA-N
}}
'''伏硫西汀'''，又名'''沃替西汀'''（[[INN|INN]]：Vortioxetine），是一种{{link-en|5-羟色胺调节剂和激动剂|Serotonin modulator and stimulator}}(SMSs)型的抗抑郁药，其药物形态为'''氢溴酸伏硫西汀'''('''Vortioxetine Hydrobromide''')。由{{link-en|灵北制药|Lundbeck}}制造的商品名为'''心达悦'''，亦有另一种商品名为'''Brintellix'''。它由制药公司Lundbeck和Takeda制造。<ref name=Label>[http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204447s004lbl.pdf US Label] {{webarchive|url=https://web.archive.org/web/20160131081621/http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204447s004lbl.pdf |date=2016-01-31 }} Last updated July 2014 after review in September, 2014.  Versions of label are available at [http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204447&DrugName=BRINTELLIX&ActiveIngred=VORTIOXETINE%20HYDROBROMIDE&SponsorApplicant=TAKEDA%20PHARMS%20USA&ProductMktStatus=1&goto=Search.Label_ApprovalHistory#labelinfo FDA index page]  Page accessed January 19, 2016</ref>

2016年，它是美国第260大处方药，涉及该药物的处方超过100万张。<ref>{{cite web |title=The Top 300 of 2019 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=clincalc.com |accessdate=22 December 2018}}</ref>

== 参考文献 ==
{{reflist}}

== 外部链接 ==
{{Pharm-stub}}

[[Category:抗抑郁药物|Category:抗抑郁药物]]